מושגי ליבה
FDA approves Posluma for PET imaging in prostate cancer.
תקציר
The US FDA has approved Posluma, a radiopharmaceutical for PET imaging in prostate cancer. Posluma binds to PSMA, aiding in disease extent evaluation. Available in the US from June 2023. Approval based on two single-arm trials showing high detection rates and minimal adverse events.
FDA Approval of Posluma
- FDA approves Posluma for PET imaging in prostate cancer.
- Posluma binds to PSMA, aiding in disease extent evaluation.
Availability and Manufacturer
- Posluma to be available in the US from June 2023.
- Manufactured and distributed by PETNET Solutions.
Comparison with Other Products
- Posluma compared to gallium-68 gozetotide for similar indications.
- Gozetotide also indicated for metastatic prostate cancer.
Approval Trials and Results
- Approval based on two single-arm trials from Blue Earth.
- LIGHTHOUSE trial showed low sensitivity but high specificity.
- SPOTLIGHT trial demonstrated high detection rates.
Adverse Events and Warnings
- Minimal adverse events reported in trials.
- Posluma PET contributes to long-term radiation exposure.
- Interpretation may vary among readers.
סטטיסטיקה
Posluma binds prostate-specific membrane antigen (PSMA).
Posluma sensitivity for predicting positive nodes ranged from 23% to 30%.
Specificity of Posluma ranged from 93% to 97%.
Adverse events included diarrhea (0.7%), blood pressure increases (0.5%), and injection site pain (0.4%).
ציטוטים
"The study showed that Posluma PET provided clinically valuable information prior to surgery." - Brian Chapin, MD